Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Debrakeleer

Urogynecology and Reconstructive Pelvic Surgery Pennington, NJ Doctor of Osteopathy

NPI 1427049311 CMS profile 200918

2 Capital Way Ste 407, Pennington, NJ 08534

Open in the dashboard

General payments

$35,660

257 records reported · program years 2019–2025

Research payments

$15,004

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,393 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Donald Debrakeleer of Pennington, NJ is reported in the CMS Open Payments database as having received $35,660 across 257 general payments and $15,004 in research payments paid to them. Separately, studies naming them as principal investigator received $2,393 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,176 31
2024 General $3,562 46
2023 General $4,381 36
2022 General $18,388 56
2021 General $962 30
2020 General $167 10
2020 Research $9,730 3
2019 General $7,025 48
2019 Research $5,274 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Debrakeleer
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Donald Debrakeleer were reported at $1,176. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Donald Debrakeleer Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $7,025 $358 $132–$1,270 $163
2020 $167 $198 $86–$642 $114
2021 $962 $361 $118–$1,182 $132
2022 $18,388 $410 $128–$1,175 $149
2023 $4,381 $434 $152–$1,344 $160
2024 $3,562 $494 $193–$1,331 $164
2025 $1,176 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Caldera Medical, Inc $22,325 25 payments
  2. Axonics Modulation Technologies, Inc. $3,500 35 payments
  3. Merck Sharp & Dohme Corporation $3,485 7 payments
  4. Bluewind Medical $1,073 11 payments
  5. Medtronic, Inc. $759 20 payments
  6. Boston Scientific Corporation $529 9 payments
  7. Coloplast Corp $419 18 payments
  8. AbbVie, Inc. $397 22 payments
  9. Sumitomo Pharma America, Inc. $358 16 payments
  10. Intuitive Surgical, Inc. $342 2 payments
  11. Other $2,474 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $21,124 9 payments
  2. Food and Beverage $6,887 214 payments
  3. Travel and Lodging $3,901 20 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,375 3 payments
  5. Gift $195 3 payments
  6. Education $178 8 payments
Products named General payments · program years 2019–2025
  1. Desara $22,325 25 payments
  2. Axonics $3,562 33 payments
  3. NEXPLANON $3,485 7 payments
  4. Bulkamid $2,951 19 payments
  5. Vertessa $2,032 2 payments
  6. REVI $1,073 11 payments
  7. INTERSTIM Sacral Nerve Stimulation $537 15 payments
  8. GEMTESA $508 22 payments
  9. Da Vinci Surgical System $342 2 payments
  10. INTERSTIM Sacral Nerve Stimulation $287 3 payments
  11. Other $3,688 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $15,004 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

560

Median for Obstetrics & Gynecology: 65

Drug cost

$149,705

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

54.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 155 $127,096
Myrbetriq Mirabegron Brand 15 $9,060
Estradiol Generic 174 $8,343
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 15 $1,156
Clobetasol Propionate Generic 17 $1,154
Solifenacin Succinate Generic 13 $1,134
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 68 $833
Nystatin-Triamcinolone Nystatin/Triamcinolone Acet Brand 17 $390
Nystatin Generic 18 $256
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $99

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$125,100

Medicare's payments for the services billed

Medicare patients

333

Average age 74

Services billed

2,973

317 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 64%
Osteoporosis 29%
Diabetes 27%
Ischemic heart disease 24%
Depression 22%
Atrial fibrillation 14%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $49
$49 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $48
$48 155 —
BOTOX
  • AbbVie, Inc. $29
$29 — —
INTRAROSA
  • MILLICENT US INC $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record